18A



NEVADA STATE BOARD OF PHARMACY

5 Damonte Ranch Pkwy Suite 206, Reno, NV 89521

TION FOR OUT-OF-STATE PHARMACY LICENSE

Fee made payable to: Nevada State Board of Pharmacy

and not transferable money order or cashier's check only)

Application must be printed legibly or typed

he answer to any question on this application is grounds for refusal or subsequent revocation of the license issued and is a violation of the

..... or the State of Nevada.

| Check box below fo | r type of ownership and complet | e all requir | icense number if making changes: PH |
|---------------------------------------|--|--------------|---|
| ☐ Publicly Traded (☐ Non Publicly Tra | Corporation – Pages 1,2,3,7 ded Corporation – Pages 1,2,4,7 | | ⁵ artnership - Pages 1,2,5,7 Sole Owner – Pages 1,2,6,7 |
| | RMATION to be completed b | | |
| Pharmacy Name: | Carepharm Pharmacy, LTC | , | |
| Physical Address: | 3535 Briarpark Drive Suite 110 | A Housto | on, Texas 77042 |
| Mailing Address: | 3535 Briarpark Drive Suite 110 | ١ | |
| City: Houston | State: | Texas | Zip Code: 77042 |
| Telephone: 281-61 | 9-2079 Fax: | 281-610-20 | 085 |
| Toll Free Number: | 800-503-7604 | _(Required | d per NAC 639.708) |
| E-mail: nancy@get | completecare.com Websi | te: N/A | |
| Managing Pharma | cist:Nancy Harris | | License Number: TX #62580 |
| TYP | E OF PHARMACY AND | SE | RVICES PROVIDED |
| Yes/f | No | Yes | s/No |
| X | □ Retail | | ☐ Off-site Cognitive Services |
| | → Hospital (# beds) | | ☑ Parenteral ** |
| | ☑ Internet | | ☑ Parenteral (outpatient) |
| | ☑ Nuclear | | ☑ Outpatient/Discharge |
| | | X | ☐ Mail Service |
| X [| ☐ Community | | ☑ Long Term Care |
| | □ Other: <u>Mail</u> | | ☑ Sterile Compounding ** |
| | | | ☑ Non Sterile Compounding |
| All bo | exes must be checked | | ☑ Mail Service Sterile Compounding ** |
| For the | ne application to be complete | | ☑ Other Services: |
| | | | |

^{**}If you check "yes" on any of these types of services, you will be <u>required</u> to make an appearance at the board meeting,

APPLICATION FOR OUT-OF STATE PHARMACY LICENSE

This page must be submitted for all types of ownership.

| Withir | the last five | (5) years: | | | | | | |
|------------------------------------|---|---|--|---|---|--|---------------------|-----------|
| 1) | any interest | , ever been cha | vner(s), shareholorged, or convicted way of a guilty pl | d of a fel- | ony or gross | Yes [| □ No [| 2 |
| 2) | Has the cor any interest registration? | , ever been den | vner(s), shareholo ied a license, per | der(s) or mit or ce | partner(s) with rtificate of | Yes | □ No l | |
| 3) | interest, eve | er been the subj | vner(s), sharehold ect of an adminis ing to the pharma | trative ac | partner(s) with any ction, board citation industry? | ١, | ☑ No l | |
| 4) | interest, eve | r been found gu to any offense f | ner(s), shareholouilty, pled guilty of ederal or state, re | r entered | partner(s) with any a plea of nolo controlled | | □ No { | \square |
| 5) | interest, eve | r surrendered a | ner(s), sharehold license, permit o er than upon volu | or certifica | partner(s) with any ate of registration ase of a facility)? | | □ No [| |
| Cobie | answer to que s of any docu sition may be | iments that iden | 5 is "yes", a sigr tify the circumsta | ned state ance or c | ment of explanation ontain an order, ag | n must be reement, | attache or other | ed. r |
| correc | i. i understa | nd that any infra | iction of the laws | of the St | attached documer ate of Nevada regu e revocation of this | Ilating the | true ai | nd |
| under correc emplo backgi | t. I hereby au yees, to concround, qualifi | If Jury, that the in Ithorize the Nev Juct any investign cation and repu | formation furnish ada State Board (ation(s) of the butation, as it may detect the state of the s | ed on thi of Pharm usiness, I deem ned | the contents there is application are tr nacy, its agents, se professional, social cessary, proper or o | ue, accura rvants and and mora desirable. | ate and | fy, |
| | |) - | | pplicatio | n, no copies or sta | mps | | |
| | | D. Pharmacist in orized Person | Charge | | 03/05/2020 Date | | | |
| | | | | | | F | Page 2 | |
| Board | Use Only | Date Processed | 3.26.202 | 0 | Amount: 500.0 | CK | | |

APPLICATION FOR OUT-OF-STATE PHARMACY LICENSE

| OWNERSHIP IS A PARTNERSHI | P Genera | al | Limited X |
|--|-------------------------|---------------------|-------------------------|
| Davids and S. M. Syprogo Dy II C | | | |
| Partnership Name: Express Rx, LLC | | | |
| Mailing Address: 3535 Briarpark Drive Su | uite 110A | | |
| City: Houston | _State: Texas | _Zip Code: | 77042 |
| Telephone Number: 281-619-2050 | Fax Number: | 800-333-97 | 97 |
| Contact Person: Christopher Miller | | | |
| List each partner and identify whether (0 Use separate sheet if necessary | G)eneral or (L)imited p | partner and | percentage of ownership |
| Name | | G or l | <u>Percentage</u> |
| John P. Monteverde, III | | L | 90% |
| Type text here | | | |
| List names of 4 largest partners and per | | | %: ^{5%} |
| Name: Mark Walz | | | |
| Name: | | | |
| Name: | | | |
| List any physician shareholders and perc | entage of ownership. | | |
| Name: | | | _%: |
| Name: | | | _%: |
| Name: | | | _%: |
| Thursday 11am-4pm | | Saturday 4 Hours | ampm |
| A Nevada business license is not required license please provide the number: | d, however if the phar | | Nevada business |

AGREED BOARD ORDER #L-19-007-B

RE: IN THE MATTER OF CAREPHARM PHARMACY LTC (PHARMACY LICENSE #24133)

BEFORE THE TEXAS STATE BOARD OF PHARMACY

On this day came on to be considered by the Texas State Board of Pharmacy (Board) the matter of pharmacy license number 24133 issued to Carepharm Pharmacy LTC (Respondent), 3535 Briar Park Drive, Suite 110A, Houston, Texas 77042.

By letter dated February 21, 2019, the Board gave preliminary notice to Respondent of its intent to take disciplinary action. This action was taken as a result of an investigation which produced evidence indicating that Respondent may have violated:

Sections 551.003(29); 562.101(b); 565.001(a)(1), (2), (12) and (13); and 565.002(a)(3) and (7) Texas Pharmacy Act, Tex. Occ. Code Ann. Title 3, Subtitle J (2017); and

Sections 281.7(a)(13); 291.11(a)(2) and (b); 291.31(35); 291.32(a)(1)(A); 291.32(a)(2)(H); and 295.3 of the Texas Pharmacy Board Rules, 22 Tex. ADMIN. CODE (2019), in that allegedly:

COUNTS

- (1) From on or about November 25, 2015, through on or about September 25, 2018, Linzay L. Kelly, while acting as an employee (pharmacist-in-charge) of Carepharm Pharmacy LTC, 3535 Briar Park Drive, Suite 110A, Houston, Texas 77042, failed to legally operate Carepharm Pharmacy LTC, in that the pharmacy ceased to engage in the business of pharmacy for a period of thirty days or longer. Specifically, on August 15, 2018, Texas State Board of Pharmacy (Board) inspectors were unable to access the pharmacy and were informed by one of the pharmacy's corporate managing officers that Mr. Kelly rarely came to the pharmacy and only dispensed one or two prescriptions per month. On August 23, 2018, the Board inspectors were granted access to the pharmacy by Mr. Kelly and requested records of dispensing for November 1, 2015, through August 23, 2018. The pharmacy's records indicate that three prescriptions were dispensed on November 24, 2015, but that no prescriptions were dispensed since that time. Subsequently, on September 25, 2018, a Board inspector observed that the pharmacy had not commenced regular operations.
- (2) On or about February 8, 2019, through on or about April 9, 2019, Carepharm Pharmacy LTC, 3535 Briar Park Drive, Suite 110A, Houston, Texas 77042, was engaged in the operation of a pharmacy in violation of Texas State Board of Pharmacy Rules, in that the pharmacy was not under the supervision of a pharmacist-in-charge.

Agreed Board Order #L-19-007-B Carepharm Pharmacy LTC Page 2

An informal conference was held in the Board's office on April 9, 2019, with Chris Miller, Chief Operating Officer and General Counsel, Express RX, LLC, on behalf of Respondent, in attendance. The informal conference was heard by a Board panel comprised of: Dennis F. Wiesner, R.Ph., Board Member; Julie Spier, R.Ph., Board Member; and Allison Vordenbaumen Benz, R.Ph., M.S., Executive Director/Secretary; with Kerstin Arnold, General Counsel. Mary Martha Murphy, Staff Attorney, was also in attendance.

By appearing at the informal conference and by signing this Order, Chris Miller, on behalf of Respondent, neither admits nor denies the truth of the matters previously set out in this Order, and agrees that the Board has jurisdiction in this matter and waives the right to notice of hearing, formal administrative hearing, and judicial review of this Order.

The parties acknowledge that this Order resolves the allegations set forth herein, and agree to the terms and conditions set forth in the ORDER OF THE BOARD below.

ORDER OF THE BOARD

THEREFORE, PREMISES CONSIDERED, the Board does hereby ORDER that:

- (1) Respondent's license shall be placed on probation for a period of two (2) years, with such period to commence thirty (30) days after the entry of this Order. During the period of probation, Respondent may actively operate as a pharmacy subject to the terms and conditions listed in this Order. Respondent shall abide by the terms of this Order, and shall not violate any pharmacy or drug statute or rule of this state, another state, or the United States with respect to pharmacy, controlled substances, and dangerous drugs.
- (2) Respondent shall pay a probation fee of one thousand two hundred dollars (\$1,200) due one hundred twenty (120) days after the entry of this Order.
- (3) Respondent shall pay an administrative penalty of four thousand dollars (\$4,000) due one hundred twenty (120) days after the entry of this Order.
- (4) Respondent shall allow Board staff to directly contact Respondent on any matter regarding the enforcement of this Order.
- (5) Failure to comply with any of the requirements in this Order constitutes a violation and shall be grounds for further disciplinary action. The requirements of this Order are subject to the Texas Pharmacy Act, Tex. Occ. Code Ann., Title 3, Subtitle J (2017), and Texas Pharmacy Board Rules, 22 Tex. Admin. Code (2019).

Agreed Board Order #L-19-007-B Carepharm Pharmacy LTC Page 3

And it is so ORDERED.

THIS ORDER IS A PUBLIC RECORD.

Kerstin Arnold, General Counsel Texas State Board of Pharmacy

SIGNED AND ENTERED ON THIS 7th day of 2019 May S STATE BOARD OF PHARMACY ATTEST: Allison Vordenbaumen Benz, R.Ph., M.S. Executive Director/Secretary Texas State Board of Pharmacy APPROVAD AS TO FORM AND AGREED TO: Chris Willer, Chief Operating Officer and General Counsel On behalf of Carepharm Pharmacy LTC APPROVED AS TO FORM:



Office of the Secretary of State

Certificate of Fact

The undersigned, as Secretary of State of Texas, does hereby certify that the document, Articles of Organization for EXPRESS Rx, LLC (file number 800336496), a Domestic Limited Liability Company (LLC), was filed in this office on April 27, 2004.

It is further certified that the entity status in Texas is in existence.

It is further certified that our records indicate JP MONTEVERDE as the designated registered agent for the above named entity and the designated registered office for said entity is as follows:

3535 BRIARPARK DR STE. 110 HOUSTON, TX - 77042 USA

In testimony whereof, I have hereunto signed my name officially and caused to be impressed hereon the Seal of State at my office in Austin, Texas on February 27, 2020.



Ruth R. Hughs Secretary of State

TID: 10268



Office of the Secretary of State Corporations Section P.O. Box 13697 Austin, Texas 78711-3697 (Form 503) Filed in the Office of the Secretary of State of Texas Filing #: 800336496 6/20/2007 Document #: 174953170004 Image Generated Electronically for Web Filing

ASSUMED NAME CERTIFICATE FOR FILING WITH THE SECRETARY OF STATE

| 1. The assumed name un | nder which the business | s or professional | service is or is to | be conducted or |
|------------------------|-------------------------|-------------------|---------------------|-----------------|
| rendered is: | | • | | |

Carepharm Pharmacy LTC

- 2. The name of the entity as stated in its certificate of formation, application for registration, application for certificate of authority, or comparable document is: EXPRESS Rx, LLC
- 3. The state, country, or other jurisdiction under the laws of which it was incorporated, organized or associated is <u>TEXAS</u> and the address of its registered or similar office in that jurisdiction is: <u>#12 Chapel Lane, New Boston, TX, USA 75570</u>
- 4. The period, not to exceed 10 years, during which the assumed name will be used is (enter number of years or a date of expiration): 06/19/2017
- 5. The entity is a : Domestic Limited Liability Company (LLC)
- 6. If the entity is required to maintain a registered office in Texas, the address of the registered office is:

#12 Chapel Lane, New Boston, TX, USA 75570

and the name of its registered agent at such address is:

Dennis Schafer

The address of the principal office (if not the same as the registered office) is:

10 Main Dr., New Boston, TX, USA 75570

7. If the entity is not required to or does not maintain a registered office in Texas, the office address in Texas is:

and if the entity is not incorporated, organized or associated under the laws of Texas, the address of its place of business in Texas is:

and the office address elsewhere is:

8. The county or counties where business or professional services are being or are to be conducted or rendered under such assumed name are:

9. The undersigned, if acting in the capacity of an attorney-in-fact of the entity, certifies that the entity has duly authorized the attorney-in-fact in writing to execute this document. The undersigned signs this document subject to the penalties imposed by law for the submission of a materially false or fraudulent instrument.

EXPRESS Rx, LLC

Name of the entity

By: John P. Monteverde III

Signature of officer, general partner, manager, representative or attorney-in-fact of the entity

NOTE

This form is designed to meet statutory requirements for filing with the secretary of state and is not designed to meet filing requirements on the county level. Filing requirements for assumed name documents to be filed with the county clerk differ. Assumed name documents filed with the county clerk are to be executed and acknowledged by the filing party, which requires that the document be notarized.

FILING OFFICE COPY

TEXAS SECRETARY of STATE RUTH R. HUGHS

BUSINESS ORGANIZATIONS INQUIRY - VIEW ENTITY

Filing Number:

800336496

Entity Type:

Domestic Limited Liability Company (LLC)

Original Date of Filing: April 27, 2004 Formation Date:

N/A

Entity Status: In existence

Tax ID:

12010571896

FEIN:

Duration:

Perpetual

Name:

EXPRESS Rx, LLC

Address:

3535 BRIARPARK DR STE 110 HOUSTON, TX 77042-5290 USA

| REGIS' | TERED AGENT | FILING HISTORY | NAMES | MANAGEMENT | ASSUMED NAMES | | CIATED |
|--------------|-----------------------------------|--------------------------------------|-------|-------------------------------|----------------------------------|--------------------|--------------------|
| View mage | Document Number 59059770003 | Filing Type Articles of Organization | | Filing Date April 27, 2004 | Effective Date April 27, 2004 | Eff. Cond No | Page Count 2 |
| V | 111217930001 | Public Information Report (PIR) | | December 31, 2005 | December 9, 2005 | No | 1 |
| V | 135383930001 | Public Information Report (PIR) | | December 31, 2006 | July 4, 2006 | No | 1 |
| V | 174892470002 | Certificate of Assumed Business N | lame | June 19, 2007 | June 19, 2007 | No | 2 |
| V | 174953170004 | Certificate of Assumed Business N | lame | June 20, 2007 | June 20, 2007 | No | 2 |
| V | 202940211684 | Tax Forfeiture | | February 8, 2008 | February 8, 2008 | No | 1 |
| K | 331503850001 | Public Information Report (PIR) | | December 31, 2009 | September 28, 2010 | No | 1 |
| X | 309065240002 | Reinstatement | | May 24, 2010 | May 24, 2010 | No | N/A |
| V | 341639630001 | Public Information Report (PIR) | | December 31, 2010 | November 22, 2010 | No | 1 |
| K | 462270580001 | Public Information Report (PIR) | | December 31, 2012 | January 22, 2013 | No | 1 |
| V | 482231020002 | Change of Registered Agent/Office | 9 | May 20, 2013 | May 20, 2013 | No | 2 |
| V | 561404210001 | Public Information Report (PIR) | | December 31, 2014 | August 15, 2014 | No | 1 |
| V | 664109490001 | Public Information Report (PIR) | | December 31, 2015 | April 4, 2016 | No | 1 |
| V | 745767430001 | Public Information Report (PIR) | | December 31, 2016 | June 21, 2017 | No | 1 |
| V | 761696930002 | Certificate of Assumed Business N | lame | September 14, 2017 | September 14, 2017 | No | 2 |
| R | 768528350001 | Public Information Report (PIR) | | December 31, 2017 | October 25, 2017 | No | 1 |
| 7/ | 892214820001 | Public Information Report (PIR) | | December 31, 2018 | May 24, 2019 | No | 1 |

Order

Return to Search

Instructions:

To place an order for additional information about a filing press the 'Order' button.

TEXAS STATE BOARD OF PHARMACY

License No. 62580

Expiration Date 02/28/2022

NANCY HARRIS
REGISTERED PHARMACIST

Allison Vordenbaumen Benz, R.Ph., M.S. Executive Director/Secretary



This certifies that the pharmacy named below is hereby licensed to operate as a Class A pharmacy.

License No. **24133**

Expiration Date: **5/31/2021**

Balances: 1

CAREPHARM PHARMACY LTC 3535 BRIAR PARK DR STE 110A HOUSTON TX 77042



Allison Vordenbaumen Benz, R.Ph., M.S. Executive Director/Secretary

MUST BE DISPLAYED IN FULL PUBLIC VIEW

AFFIDAVIT for Out-of-State Pharmacy License

| STATE OF TEXAS) |
|--|
| HARRIS COUNTY) |
| I, NANCY HARRS , hereby certify that the assertions in this Affidavit |
| are true and correct to the best of my knowledge and belief, and state as follows: |
| 1. I am the YHARMCIST for CAREPHARIN (the |
| Pharmacy), and in that capacity, I am authorized to speak on the Pharmacy's behalf. |
| 2. I certify that upon licensure, the Pharmacy will not sell or ship compounded sterile |
| products unto the state of Nevada, as indicated on the Pharmacy's application for a Nevada Out- of- |
| State Pharmacy License. |
| 3. I understand and acknowledge that the Pharmacy and any of its Nevada- |
| registered/licensed staff members may be subject to discipline by the Board if the Pharmacy sells or |
| ships any compounded sterile product into Nevada without first obtaining written authorization from |
| the Board to do so. |
| 4. I certify that if the Pharmacy ever decides to sell or ship any compounded sterile |
| product into Nevada, the Pharmacy, through an authorized representative, will first notify the Board |
| and obtain written approval to sell and ship such products into Nevada. |
| 5. I understand that if the Pharmacy seeks approval to sell or ship compounded sterile |
| product into Nevada, an authorized representative of the Pharmacy may be required to appear |
| before the Board to answer questions before such approval is granted. |
| FURTHER AFFIANT SAYETH NOT. |
| I, MANCY HAR adhereby swear under penalty of perjury that the assertions of this |
| affidavit are true. |
| SUBSCRIBED AND SWORN TO |
| before me, a notary public this |
| 77 day of <u>FEBRUAILY</u> , 2020. |
| AIMEE COATES Notary ID #129295573 My Commission Expires March 1, 2021 |

STATEMENT OF RESPONSIBILITY FOR PHARMACIES LOCATED OUTSIDE OF NEVADA

| 1, NANCY FARRES |
|--|
| Responsible Person of CARRARM PHARMACI |
| hereby acknowledge and understand that in addition to the corporation's, any owner(s), |
| shareholder(s) or partner(s) responsibilities, may be responsible for any violations of pharmacy law |
| that may occur in a pharmacy owned or operated by said corporation. |
| I further acknowledge and understand that the corporation's any owner(s) also as believed. |
| I further acknowledge and understand that the corporation's, any owner(s), shareholder(s) |
| or partner(s)may be named in any action taken by the Nevada State Board of Pharmacy against a |
| pharmacy owned by or operated by said corporation. |
| I further acknowledge and understand that the correction's account () |
| I further acknowledge and understand that the corporation's, any owner(s), shareholder(s) |
| or partner(s) cannot require or permit the pharmacist(s) in said pharmacy to violate any provision |
| of any local, state or federal laws or regulations pertaining to the practice of pharmacy. |
| |
| |
| Cerus Sarie the |
| Original Signature of Person Authorized to Submit Application, no copies or stamps |
| NANCI F. HARRIS 1/20/20 |
| Print Name of Authorized Person Date |

18B

NEVADA STATE BOARD OF PHARMACY

PH04213

985 Damonte Ranch Pkwy Suite 206, Reno, NV 89521

APPLICATION FOR OUT-OF-STATE PHARMACY LICENSE

\$500.00 Fee made payable to: Nevada State Board of Pharmacy

(non-refundable and not transferable money order or cashier's check only)

Application must be printed legibly or typed

Any misrepresentation in the answer to any question on this application is grounds for refusal or denial of the application or subsequent revocation of the license issued and is a violation of the laws of the State of Nevada.

| ☑New Pharmacy or ☐Ownership Change (Provide cu Check box below for type of ownership and complete all ☐ Publicly Traded Corporation — Pages 1,2,3,7 ☐ Non Publicly Traded Corporation — Pages 1,2,4,7 *Script2U LLC is a Limited Liability Company Date of Formation GENERAL INFORMATION to be completed by all | required forms. Partnership - Pages 1,2,5,7 Sole Owner - Pages 1,2,6,7 n: 06/05/2019 State of Formation: Delaware |
|--|--|
| Pharmacy Name: Script2U LLC | |
| Physical Address: 4971 Southridge Blvd., Ste. 115 | , Memphis, TN 38141 |
| Mailing Address: C/O McKesson / Regulatory Affairs, 665 | 1 Gate Parkway |
| City: Jacksonville State: FL | Zip Code: <u>32256</u> |
| Telephone: (833) 672-7478 Fax: (844) | |
| Toll Free Number: (833) 672-7478 (Rec | quired per NAC 639.708) |
| E-mail: Script2U@McKesson.com Website: | |
| Managing Pharmacist: Katherine Therese Twomey | License Number: TN #37225 |
| TYPE OF PHARMACY AND | SERVICES PROVIDED |
| Yes/No | Yes/No |
| □ ⊠ Retail | ☐ ☑ Off-site Cognitive Services |
| ☐ ☑ Hospital (# beds) | □ ☑ Parenteral ** |
| □ ☑ Internet | □ ☑ Parenteral (outpatient) |
| □ ⊠ Nuclear | □ ☑ Outpatient/Discharge |
| □ | ☑ □ Mail Service |
| ☑ □ Community | □ |
| □ ☑ Other: | ☐ ☑ Sterile Compounding ** |
| | □ ☑ Non Sterile Compounding |
| All boxes must be checked | ☐ ☑ Mail Service Sterile Compounding ** |
| For the application to be complete | ☑ Other Services: Fulfillment; Central-Fill |
| | |

^{**}If you check "yes" on any of these types of services, you will be <u>required</u> to make an appearance at the board meeting,

APPLICATION FOR OUT-OF STATE PHARMACY LICENSE

This page must be submitted for all types of ownership.

| Within the last five (5) years: | Within | the | last | five | (5) | vears: | |
|---------------------------------|--------|-----|------|------|-----|--------|--|
|---------------------------------|--------|-----|------|------|-----|--------|--|

| Board | Use Only Date Processed: Amount: | |
|----------------------------|--|------------------------------------|
| | ame of Authorized Person Date | Page 2 |
| | House Thurse Twomey al Signature of Person Authorized to Submit Application, no copies or stamp Therese Twomey 3113136 | s |
| under correct employ | read all questions, answers and statements and know the contents thereof. penalty of perjury, that the information furnished on this application are true, t. I hereby authorize the Nevada State Board of Pharmacy, its agents, servates, to conduct any investigation(s) of the business, professional, social and ound, qualification and reputation, as it may deem necessary, proper or designated. | accurate and nts and d moral |
| correc | by certify that the answers given in this application and attached documental t. I understand that any infraction of the laws of the State of Nevada regulat ion of an authorized pharmacy may be grounds for the revocation of this pe | ing the |
| Copies | inswer to question 1 through 5 is "yes", a signed statement of explanation mades of any documents that identify the circumstance or contain an order, agree ition may be required. | ust be attached. ment, or other |
| 5) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever surrendered a license, permit or certificate of registration voluntarily or otherwise (other than upon voluntary close of a facility)? | Yes □ No ⊠ |
| 4) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been found guilty, pled guilty or entered a plea of nolo contendere to any offense federal or state, related to controlled substances? | Yes □ No ⊠ |
| 3) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been the subject of an administrative action, board citation, site fine or proceeding relating to the pharmaceutical industry? Please see Attachment #5 | Yes ⊠ No □ |
| 2) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been denied a license, permit or certificate of registration? | Yes □ No ⊠ |
| 1) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been charged, or convicted of a felony or gross misdemeanor (including by way of a guilty plea or no contest plea)? | Yes □ No ⊠ |

APPLICATION FOR OUT-OF-STATE PHARMACY LICENSE

OWNERSHIP IS A NON PUBLICY TRADED CORPORATION Limited Liability Company State of Incorporation: state of formation: Delaware

| etate of moorporation. |
|---|
| Parent Company if any: Script2U Holdings LLC |
| Mailing Address: C/O McKesson / Regulatory Affairs, 6651 Gate Parkway |
| City: State: FL Zip: 32256 |
| Telephone: (833) 672-7478 |
| Contact Person: Katherine Therese Twomey |
| For any corporation non publicly traded, disclose the following: |
| 1) List top 4 persons to whom the shares were issued by the corporation? |
| a) No individual owners. Script2U Holdings LLC is the sole owner. |
| Name Address |
| b) |
| Name Address |
| c) |
| Name Address |
| d)Name Address |
| Name Address |
| 2) Provide the number of shares issued by the corporation. N/A |
| 3) What was the price paid per share? N/A |
| 4) What date did the corporation actually receive the cash assets? N/A |
| 5) Provide a copy of the corporation's stock register evidencing the above information |
| List any physician shareholders and percentage of ownership. |
| Name: N/A %:%: |
| Name:%: |
| Hours of Operation for the pharmacy: |
| Monday thru Friday 08:00 am 4:30 pm Saturday Closed ampr |
| Sunday Closedampm 24 Hours |
| Pharmacist on Call M-F 4:30pm - 6:00pm and Saturday 8:00am - 6:00pm |
| A Nevada business license is not required, however if the pharmacy has a Nevada business license please provide the number: N/A |
| Page 4 |

Must be included with the application for a non publicly traded corporation

<u>Certificate of Corporate Status</u> (also referred to as Certificate of Good Standing). The Certificate is obtained from the Secretary of State's office in the State where incorporated. The Certificate of Corporate status must be dated within the last 6 months. Please see Attachment #1

<u>List of officers and directors</u>

Script2U LLC has one (1) member: Script2U Holdings, LLC and the principal officers listed below: Clay Courville, President

Edward Franklin Childress, III, Vice-President and Treasurer Katherine Therese Twomey, Vice-President and Secretary

STATEMENT OF RESPONSIBILITY FOR PHARMACIES LOCATED OUTSIDE OF NEVADA

I, Katherine Therese Twomey

| Responsible Person of Script2U LLC |
|--|
| hereby acknowledge and understand that in addition to the corporation's, any owner(s), |
| shareholder(s) or partner(s) responsibilities, may be responsible for any violations of pharmacy law |
| that may occur in a pharmacy owned or operated by said corporation. |
| I further acknowledge and understand that the corporation's, any owner(s), shareholder(s) |
| or partner(s)may be named in any action taken by the Nevada State Board of Pharmacy against a |
| pharmacy owned by or operated by said corporation. |
| |
| I further acknowledge and understand that the corporation's, any owner(s), shareholder(s) |
| or partner(s) cannot require or permit the pharmacist(s) in said pharmacy to violate any provision |
| of any local, state or federal laws or regulations pertaining to the practice of pharmacy. |
| |
| |
| Criginal Signature of Person Authorized to Submit Application, no copies or stamps |
| Katherine Therese Two mey Print Name of Authorized Person Al 12/20 Date |

AFFIDAVIT for Out-of-State Pharmacy License

| STATE OF Tennessee) ss. |
|--|
| Shelby COUNTY) |
| |
| I, Katherine Therese Twomey , hereby certify that the assertions in this Affidavi |
| are true and correct to the best of my knowledge and belief, and state as follows: |
| 1. I am the VP and Secretary and PIC for Script2U LLC (the |
| Pharmacy), and in that capacity, I am authorized to speak on the Pharmacy's behalf. |
| 2. I certify that upon licensure, the Pharmacy will not sell or ship compounded sterile |
| products unto the state of Nevada, as indicated on the Pharmacy's application for a Nevada Out- of |
| State Pharmacy License. |
| 3. I understand and acknowledge that the Pharmacy and any of its Nevada- |
| registered/licensed staff members may be subject to discipline by the Board if the Pharmacy sells of |
| ships any compounded sterile product into Nevada without first obtaining written authorization from |
| the Board to do so. |
| 4. I certify that if the Pharmacy ever decides to sell or ship any compounded sterile |
| product into Nevada, the Pharmacy, through an authorized representative, will first notify the Board |
| and obtain written approval to sell and ship such products into Nevada. |
| 5. I understand that if the Pharmacy seeks approval to sell or ship compounded sterile |
| product into Nevada, an authorized representative of the Pharmacy may be required to appear |
| before the Board to answer questions before such approval is granted. |
| FURTHER AFFIANT SAYETH NOT. |
| I, Katherine Therese Twomey, do hereby swear under penalty of perjury that the assertions of this |
| affidavit are true. |
| Lothor uno Mero so Tromay |
| SUBSCRIBED AND SWORN TO |
| before me, a notary public this day of 2020 |
| STATE OF |
| NOTARY PUBLIC TENNESSEE |

Attachment #1 Certificate of Good Standing

Delaware The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF

DELAWARE, DO HEREBY CERTIFY "SCRIPT2U LLC" IS DULY FORMED UNDER THE

LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A

LEGAL EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF

THE SECOND DAY OF JANUARY, A.D. 2020.

AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "SCRIPT2U LLC" WAS FORMED ON THE FIFTH DAY OF JUNE, A.D. 2019.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL TAXES HAVE BEEN ASSESSED TO DATE.

7455099 8300 SR# 20200010239

You may verify this certificate online at corp.delaware.gov/authver.shtml

Jeffrey W Bullack, Secretary of State

Authentication: 202103203

Date: 01-02-20

Attachment #2 Letter of Good Standing

Last Updated: 3/18/2020

For more information, please contact Health Care Facilites (615)741-7221 or 800-778-4504

Health Care Facilities

Licensed Facilities

Current Listings

Type = Pharmacy County = All Results = 1

Click here to return to the search page

Script2U LLC 4971 Southridge Blvd., Ste 115 1 Memphis, TN 38141 636-751-8405

Rank: Pharmacy
Pharmacist: TWOMEY, KATHERINE THERESE

Facility License Number: 00006851 Status: Licensed Date of Original Licensure: 03/17/2020 Date of Expiration: 03/31/2022 No Disciplinary Actions Attachment #3
Pharmacy License



State of Tennessee Department of Health

1 04 9 8

TENNESSEE BOARD OF PHARMÁCY
PHARMACY
SCRIPT2U LLC
4971 SOUTHRIDGE BLVD., STE 115
MEMPHIS TN 38141

This is to certify that all requirements of the State of Tennessee have been met.

ID NUMBER: 0000006851

EXPIRATION DATE: 03/31/2022

Gaha W Sidwell
DIRECTOR, HEALTH RELATED BOA

WAS THE CELLY TO

COMMISSION

DCF171

Script2U LLC is a wholly-owned subsidiary of McKesson Corporation, a publicly-traded McKesson Corporation and its subsidiaries (hereinafter "McKesson") delivers pharmaceutical and medical products and business services to retail pharmacies and institutional providers like hospitals and health systems throughout North America and globally. Over the past 185 years, McKesson has developed multiple businesses that operate pharmacies, medical supply distribution centers, wholesale drug distribution centers, 3PL facilities, repackaging facilities, and other entities subject to federal and state regulation. Currently, McKesson owns and operates over 97 facilities in the United States that are licensed, permitted, or registered with the respective state agency with jurisdiction over its business type. Due to the breadth of its operations, it is practical that we limit this summary to disciplinary actions taken against these facilities during the last five years or the time frame specified in the question. The information in this statement is provided to the best of our knowledge and belief and includes all public disciplinary actions. This statement does not include any fines that are deemed non-disciplinary by the issuing state (for example, it does not include nondisciplinary Citations and Fines issued by California). Please let us know if your agency requires information regarding non-disciplinary fines.

Please note that the disciplinary actions described below do NOT pertain to Script2U LLC operations, only to its indirect owner, McKesson.

McKesson entered into agency orders with the Boards of Pharmacy in Colorado, Georgia, and Oklahoma between 2009 and 2012. The terms of these final agency orders required that McKesson take certain actions to maintain its wholesale distributor licenses in these states, such as pay a fine. In 2014 McKesson disclosed these final agency orders to the Michigan Board of Pharmacy, who subsequently filed a complaint on the grounds that it is a violation of Michigan pharmacy law for a licensee to be the subject of administrative action in another state. The Michigan Board of Pharmacy asked McKesson to prove compliance with the agency orders in Colorado, Georgia, and Oklahoma. McKesson promptly supplied proof of compliance to the Michigan Board of Pharmacy. The matter was resolved via consent order, pursuant to which McKesson accepted a reprimand and a fine. The Michigan Board of Pharmacy determined that McKesson has accepted responsibility in Colorado, Georgia, and Oklahoma and taken corrective measures to prevent re-occurrences of the issues that gave rise to those agency orders.

In 2014, **McKesson** entered into a Final Consent Order with the <u>Maryland Board of Pharmacy</u> concerning its Landover, Maryland distribution center (the "Landover DC"), which closed in May 2012. The Final Consent Order resolved allegations that, from January 2008 – November 2009, McKesson's Landover DC purchased approximately \$2.95 million of prescription drugs/devices from a wholesale distributor that was not licensed in Maryland. McKesson paid a \$30,000 fine in November 2014.

In 2015, **McKesson** entered into a Final Consent Order with the <u>Maryland Board of Pharmacy</u> concerning Landover DC. The Final Consent Order resolved allegations that, from January 2009 – December 2009, McKesson's Landover DC purchased approximately \$2.5 million of prescription drugs/devices from an unlicensed wholesale distributor. Since the period when the alleged violations occurred, McKesson has made numerous enhancements and significant additional investments in its compliance program related to the acquisition and distribution of

In January 2017, **McKesson** entered into an agreement (the "DEA Settlement") with the <u>DEA and DOJ</u> to settle all potential administrative and civil claims stemming from investigation into McKesson's practices for identifying and reporting suspicious orders of controlled substances, beginning in 2009. Under the settlement McKesson agreed to pay \$150 million and to implement remedial measures related to its controlled substances monitoring program. In addition, the following distribution centers' DEA registrations are temporarily suspended for the following specified products and time periods: Aurora, Colorado - all controlled substances for three years; Livonia, Michigan - all controlled substances for two years; Washington Court House, Ohio - all controlled substances for the two-year period following completion of the Livonia suspension; and Lakeland, Florida - hydromorphone products for one year. The terms of the suspensions of the Livonia, Washington Court House, and Lakeland facilities permit those distribution centers to continue shipping controlled substances to customers that purchase products under McKesson's contract with the Department of Veterans Affairs.

In March 2017, in response to the DEA Settlement, the New York State Department of Health, Bureau of Narcotic Enforcement, suspended the Class 2A (Out-of-State) controlled substance license for McKesson's Livonia, Michigan distribution center. The permit has been suspended until January 1, 2019, consistent with the suspension timeframes of the DEA Settlement. No other suspensions or fines were issued, and the New York action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In June 2017, in response to the DEA Settlement, the <u>Idaho Board of Pharmacy</u> suspended the Controlled Substance Registrations of **McKesson** distribution centers in Washington Court House, Ohio and the Livonia, Michigan. The Livonia Idaho controlled substance registration has been suspended for two years, effective 6/17/17 to 1/17/19. The Washington Court House Idaho controlled substance registration will be suspended for two years, effective 1/18/19 to 1/18/21. No other suspensions or fines were issued, and the Idaho action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In September 2017, in response to the DEA Settlement, the <u>Colorado State Board</u> of Pharmacy placed the wholesaler registration of **McKesson**'s distribution center in Aurora, Colorado (14500 39th Ave) on probation. McKesson also agreed to pay a fine of \$45,000, with an additional surcharge of 15%, totaling \$51,750. No other suspensions or fines were issued.

In November 2017, in response to the DEA Settlement, the <u>Louisiana Board of Pharmacy</u> suspended the Controlled Substance Registrations of **McKesson** distribution centers in Washington Court House, Ohio and the Livonia, Michigan. The Livonia Louisiana controlled substance registration has been suspended for two years, effective 6/17/17 to 1/17/19. The Washington Court House Louisiana controlled substance registration will be suspended for two years, effective 1/18/19 to 1/18/21. McKesson also agreed to reimburse the Louisiana Board \$250.00 for administrative costs No other suspensions or fines were issued, and the Louisiana action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In December 2017, in response to the DEA Settlement, the <u>New Hampshire Board of Pharmacy</u> suspended the right of **McKesson's** distribution centers in Washington Court House,

Ohio and Livonia, Michigan to distribute controlled substances. The Livonia distribution center's ability to distribute controlled substance has been suspended, effective 12/12/17 to 1/17/19. The Washington Court House distribution center's ability to distribute controlled substance will be suspended for two years, effective 1/18/19 to 1/18/21. McKesson also agreed to pay an administrative fine of \$2,000.00. No other suspensions of fines were issued, and the New Hampshire action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In February 2018, in response to the DEA Settlement, the <u>Florida Department of Business & Professional Regulation</u> and **McKesson Corporation** entered in a Settlement Agreement as disposition of an alleged violation of Section 499.0121(10), Florida Statutes (2008-2017), by operating not in compliance with applicable federal laws and regulations. McKesson also agreed to pay a settlement amount of \$10,000.00. No other suspensions of fines were issued.

On March 14, 2018, the <u>Iowa Board of Pharmacy</u> voted to issue Controlled Substance Act registrations for two of **McKesson Corporation**'s distribution centers. Because these two facilities are impacted by the DEA settlement, the Board issued the registrations pursuant to Controlled Substances Act Registration by Consent Agreements (the "Agreements"). The Agreements are applicable only to the registrations and do not impose discipline upon the distribution center's wholesale permits. The general terms of the Agreements are summarized below:

- Livonia, Michigan the facility's Iowa controlled substance registration was issued but is restricted. The facility is prohibited from distributing controlled substances into the state until 1/17/2019 except for various exceptions that mirror exceptions in the DEA settlement; and
- Washington Court House, Ohio the facility's Iowa controlled substance registration was
 issued but is restricted and the facility will be prohibited from distributing controlled
 substances into the state from 1/18/19 to 1/18/2021 except for various exceptions that
 mirror exceptions in the DEA settlement.

On March 20, 2018, in response to the DEA Settlement, the <u>Maryland State Board of Pharmacy</u> suspended the right of **McKesson**'s distribution center in Washington Court House, Ohio to distribute controlled substances. The distribution center's ability to distribute controlled substance will be suspended for two years, effective 1/18/19 to 1/18/21. No other suspensions of fines were issued, and the Maryland action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

On April 9, 2018, in response to the DEA Settlement, **McKesson** entered into stipulations with the <u>Utah Board of Pharmacy</u>. The stipulations apply to the McKesson distribution centers located in Washington Court House, Ohio and Aurora, Colorado. The Washington Court House facility's right to distribute controlled substances into Utah has been suspended effective 1/18/2019 to 1/18/2021 and the Aurora facility's right to distribute controlled substances into Utah has been suspended from 4/9/2018 to 1/17/2020. Utah's action mirrors the suspension and exceptions agreed to in McKesson's settlement with the DEA. The Utah Board of Pharmacy's action mirrors the suspension and exceptions agreed to in McKesson's settlement with the DEA Settlement.

In 2018 May **McKesson Corporation** was fined by the <u>California Board of Pharmacy</u> related to the fact that its Memphis, TN distribution center failed to timely notify the state of California when their designated representative left the company. The designated representative required by the home state was always in place. The new designated representative is now and has been since December 1, 2017 fully licensed. McKesson paid \$1,000 fine. The fine is related to a non-disciplinary action.

On May 31, 2018, **McKesson** entered into a consent agreement with the <u>Oregon Board of Pharmacy</u> (the "Oregon Consent"). The Oregon Consent applies to the McKesson distribution center located in Washington Court House, Ohio. The Washington Court House facility's right to distribute controlled substances into Oregon has been suspended effective 1/18/2019 to 1/18/2021. The Oregon Consent originates from McKesson's report to Oregon of a settlement that McKesson entered into with the Idaho Board of Pharmacy. The Idaho settlement, in turn, was based on the settlement that McKesson entered into the DEA entered into on January 17, 2017 (the "DEA Settlement"). Note, the suspension period imposed by Oregon aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On December 17, 2018, **McKesson** entered into a consent agreement with the <u>Virginia Board of Pharmacy</u> (the "Virginia Consent"). The Virginia Consent applies to the McKesson distribution center located in Livonia, Michigan. The Livonia facility's right to distribute controlled substances into Virginia has been suspended until 1/17/2019. Note, the suspension period imposed by Virginia aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On January 14, 2019 **McKesson Corporation** entered into a settlement for a payment of \$10,000 on behalf of a now-closed facility in <u>Connecticut</u> (see attached). This settlement arose from the failure of employees of McKesson's contracted local delivery carrier to secure their vehicles when making deliveries within Connecticut. Importantly, there were never any reports of theft or loss based on this failure and McKesson's contract with the local delivery carrier specifically required security measures, including the securing of vehicles. However, despite multiple warnings from McKesson, the drivers did not comply with this requirement. When made aware of the Connecticut Agency's concern, McKesson hosted a training session, along with the Connecticut Agency, for all of the local delivery carrier's drivers.

On February 27, 2019, **McKesson** entered into a consent agreement with the <u>Wisconsin Pharmacy Examining Board</u> (the "Wisconsin Consent"). The Wisconsin Consent applies to McKesson distribution centers located in Livonia, Michigan and Washington Court House, Ohio. The Livonia, Michigan facility was fined and the facility's right to distribute controlled substances into Wisconsin has been suspended from 1/17/17 to 1/17/19. The Washington Court House, Ohio facility was fined and the facility's ability to distribute controlled substances into Wisconsin has been suspended effective 1/17/19 to 1/17/2021. Note, the suspension period imposed by Wisconsin aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On May 10, 2019, **McKesson** entered into the stipulated agreement with the <u>New Mexico</u> <u>Board of Pharmacy</u> (the "New Mexico Agreement"). The New Mexico Agreement applies to the McKesson distribution center located in Washington Court House, Ohio. The facility's ability to distribute controlled substances into New Mexico has been suspended until February 16, 2021. Note, the suspension period imposed by Wisconsin aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On May 21, 2019, **McKesson** entered into a consent order with the <u>Alabama Board of Pharmacy</u> (the "Alabama Consent"). The Alabama Consent applies to the McKesson distribution centers located in Washington Court House, Ohio, Aurora, Colorado and Livonia, Michigan. The facilities were subject to a fine under the terms of the Alabama Consent: fifteen thousand dollars (\$15,000) by each permit. The Alabama Consent originates from McKesson's report to Alabama of a settlement that McKesson entered into with the DEA on January 17, 2017 (the "DEA Settlement").

On June 10, 2019, in response to the DEA Settlement, **McKesson** entered into a consent agreement with the <u>Virginia Board of Pharmacy</u> (the "WCH Virginia Consent"). The WCH Virginia Consent applies to the McKesson distribution center located in Washington Court House, Ohio. The facility's right to distribute controlled substances into Virginia has been suspended from June 10, 2019 to February 16, 2021. The WCH Virginia Consent originates from McKesson's report to Virginia of settlements that McKesson entered into with the DEA and Louisiana Board of Pharmacy.

On July 29, 2019, in response to the DEA Settlement, the <u>California Board of Pharmacy</u> approved a Stipulated Settlement and Disciplinary Order for Public Reproval with **McKesson** (the "California Settlement"). The California Settlement is effective on August 28, 2019 and applies to both the Washington Court House, Ohio and Livonia, MI distribution centers. Subject to the terms of the settlement, McKesson was issued a public letter of Reproval, agreed to pay \$4,000 in investigative fees.

On August 29, 2019 **McKesson** received a Letter of Admonition from the <u>Colorado State</u> <u>Board of Pharmacy</u> due to the delinquent notification of a change in the Designated Representative at its distribution center located at in O'Fallon, MO ("McKesson St. Louis").

On August 29, 2019 **McKesson** entered into a Stipulation and Final Agency Order with the <u>Colorado State Board of Pharmacy</u> regarding the delinquent notification of a change in the Designated Representative at its distribution center located in Aurora. IL ("**McKesson Chicagoland**"). The terms of the settlement included a fine in the amount of \$1,150.00.

On January 7, 2020 McKesson entered into a Consent Agreement and Final Order with the <u>Iowa Board of Pharmacy</u> regarding pseudoephedrine products had not been included in the McKesson's Clear Lake, IA facility's annual controlled substance inventory and that butalbital products continued to be treated as legend drugs after such products became schedule III products in the state on June 26, 2019.


On January 14, 2020 McKesson Medical-Surgical Inc. entered into a Consent Agreement with the <u>Arizona State Board of Pharmacy</u>, regarding its Tempe, AZ distribution center, for

shipping prescription drugs to an entity that was not properly licensed to receive them. A monetary civil penalty of \$1,000 was imposed and paid on January 14, 2020.

Please note that the disciplinary actions described below do NOT pertain to Script2U LLC operations, only to its indirect owner, McKesson.

If any additional information is required, please contact us via email at mckessonlicesning@mckesson.com.

18C



NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy Suite 206, Reno, NV 89521

APPLICATION FOR OUT-OF-STATE PHARMACY LICENSE

\$500.00 Fee made payable to: Nevada State Board of Pharmacy

(non-refundable and not transferable money order or cashier's check only)

Application must be printed legibly or typed

Any misrepresentation in the answer to any question on this application is grounds for refusal or denial of the application or subsequent revocation of the license issued and is a violation of the laws of the State of Nevada.

| New Pharmacy or Ownership Change (Provide current license number if making changes: PH Check box below for type of ownership and complete all required forms. | | |
|---|---|--|
| | ☐ Partnership - Pages 1 2 5 7 | |
| GENERAL INFORMATION to be completed by all types of ownership | | |
| Pharmacy Name: ScriptHero Pharmacy LLC | | |
| Physical Address: 2 Miranova Pl 10th Fl, Columbu | s, OH 43215 | |
| Mailing Address: 2 Miranova Pl 10th Fl | | |
| City: Columbus State: OH | Zip Code: 43215 | |
| | 1-232-8850 | |
| Toll Free Number: 866-747-4276 (Reg | uired per NAC 639.708) | |
| E-mail: kdresbach@covermymeds.com Website: www.ScriptHero.com/pharmacy | | |
| Managing Pharmacist: Kyle Dresbach | License Number: OHIO - 03234033 | |
| | | |
| Yes/No | SERVICES PROVIDED | |
| □ ⊠ Retail | Yes/No | |
| ☐ ☑ Hospital (# beds) | ☐ ☑ Off-site Cognitive Services | |
| □ ⊠ Internet | □ ☑ Parenteral ** | |
| □ ⊠ Nuclear | ☐ ☑ Parenteral (outpatient) | |
| ☐ ☑ Ambulatory Surgery Center | ☐ ☑ Outpatient/Discharge | |
| ☐ ☑ Community | ☐ ☑ Mail Service | |
| ☐ ☐ Other: consulting | □ ☑ Long Term Care | |
| non-dispensing pharmacy | □ ⊠ Sterile Compounding ** | |
| All boxes must be checked | □ ☑ Non Sterile Compounding | |
| | Mail Service Sterile Compounding ** | |
| For the application to be complete | ☑ Other Services: Digital Pharmacy Services | |
| | | |

^{**}If you check "yes" on any of these types of services, you will be <u>required</u> to make an appearance at the board meeting,

APPLICATION FOR OUT-OF STATE PHARMACY LICENSE

This page must be submitted for all types of ownership.

| Withir | the last five (5) years: | | | |
|---|--|------------|--|--|
| 1) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been charged, or convicted of a felony or gross misdemeanor (including by way of a guilty plea or no contest plea)? | Yes □ No 🛭 | | |
| 2) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been denied a license, permit or certificate of registration? | Yes □ No 🏻 | | |
| 3) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been the subject of an administrative action, board citation, site fine or proceeding relating to the pharmaceutical industry? | Yes ⊠ No □ | | |
| 4) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever been found guilty, pled guilty or entered a plea of nolo contendere to any offense federal or state, related to controlled substances? | Yes □ No 🛭 | | |
| 5) | Has the corporation, any owner(s), shareholder(s) or partner(s) with any interest, ever surrendered a license, permit or certificate of registration voluntarily or otherwise (other than upon voluntary close of a facility)? | Yes □ No 🏻 | | |
| If the answer to question 1 through 5 is "yes", a signed statement of explanation must be attached. Copies of any documents that identify the circumstance or contain an order, agreement, or other disposition may be required. Please see Attachment 5. | | | | |
| correc | by certify that the answers given in this application and attached documental t. I understand that any infraction of the laws of the State of Nevada regulation of an authorized pharmacy may be grounds for the revocation of this pe | ing the | | |
| I have read all questions, answers and statements and know the contents thereof. I hereby certify, under penalty of perjury, that the information furnished on this application are true, accurate and correct. I hereby authorize the Nevada State Board of Pharmacy, its agents, servants and employees, to conduct any investigation(s) of the business, professional, social and moral background, qualification and reputation, as it may deem necessary, proper or desirable. | | | | |
| Origina | al Signature of Person Authorized to Submit Application, no copies or stamp | S | | |
| | omas Gilbert Traylor, III Jame of Authorized Person Date | | | |
| 1 111111 | lame of Authorized Person Date | Page 2 | | |
| Board | Use Only Date Processed: FEB 1 3 2020 Amount: 500.00 |) | | |

APPLICATION FOR OUT-OF-STATE PHARMACY LICENSE

OWNERSHIP IS A NON PUBLICY TRADED CORPORATION

| State of Incorporation: Delaware | | | |
|---|--|--|--|
| Parent Company if any: ScriptHero Pharmacy Holdings LLC | | | |
| Mailing Address: 2 Miranova Pl 10th Fl | | | |
| City: Columbus State: OH Zip: 43215 | | | |
| Telephone: 866-747-4276 Fax: 614-232-8850 | | | |
| Contact Person: Kyle Dresbach | | | |
| For any corporation non publicly traded, disclose the following: | | | |
| List top 4 persons to whom the shares were issued by the corporation? | | | |
| | | | |
| a) No individual owners. ScriptHero Pharmacy Holdings LLC is the sole owner. Name Address | | | |
| b) | | | |
| Name Address | | | |
| c) | | | |
| Name Address | | | |
| d)Name Address | | | |
| | | | |
| 2) Provide the number of shares issued by the corporation | | | |
| What was the price paid per share? | | | |
| What date did the corporation actually receive the cash assets?n/a | | | |
| Provide a copy of the corporation's stock register evidencing the above information | | | |
| List any physician shareholders and percentage of ownership. | | | |
| Name: | | | |
| Name:%: | | | |
| dours of Operation for the pharmacy: | | | |
| Monday thru Friday 9:00AM am 5:00 PM pm Saturdayampn | | | |
| Sundayampm 24 Hours | | | |
| A Nevada business license is not required, however if the pharmacy has a Nevada business icense please provide the number: _n/a | | | |
| Page 4 | | | |

Must be included with the application for a non publicly traded corporation

<u>Certificate of Corporate Status</u> (also referred to as Certificate of Good Standing). The Certificate is obtained from the Secretary of State's office in the State where incorporated. The Certificate of Corporate status must be dated within the last 6 months.

List of officers and directors

The senior officer of ScriptHero Pharmacy LLC is:

Thomas Gilbert Traylor, III, Senior Vice President, Strategic Initatives

ScriptHero Pharmacy LLC is a member managed limited liability company and therefore has no directors.

STATEMENT OF RESPONSIBILITY FOR PHARMACIES LOCATED OUTSIDE OF NEVADA

| I, I nomas Gilbert | raylor, III | |
|---------------------------------|----------------------------------|---|
| Responsible Person of Sc | criptHero Pharmacy LLC | |
| hereby acknowledge and un | derstand that in addition to the | corporation's, any owner(s), |
| shareholder(s) or partner(s) | | nsible for any violations of pharmacy law |
| I further acknowledge | and understand that the corpo | pration's, any owner(s), shareholder(s) |
| | | ada State Board of Pharmacy against a |
| pharmacy owned by or opera | | |
| or partner(s) cannot require of | | oration's, any owner(s), shareholder(s) said pharmacy to violate any provision to the practice of pharmacy. |
| Original Signature of Person | Authorized to Submit Applicati | ion, no copies or stamps |
| | | |
| Thomas Gilbert Traylor, III | | 2/7/20 |
| Print Name of Authorized Per | rson | Date |

AFFIDAVIT for Out-of-State Pharmacy License

| STATE OF DING) |
|--|
| STATE OF OING) ss. Franklin COUNTY) |
| I, Kyle Dresbach , hereby certify that the assertions in this Affidavit |
| are true and correct to the best of my knowledge and belief, and state as follows: |
| 1. I am the Pharmacist-in-Charge for ScriptHero Pharmacy LLC (the |
| Pharmacy), and in that capacity, I am authorized to speak on the Pharmacy's behalf. |
| I certify that upon licensure, the Pharmacy will not sell or ship compounded sterile |
| products unto the state of Nevada, as indicated on the Pharmacy's application for a Nevada Out- of- |
| State Pharmacy License. |
| 3. I understand and acknowledge that the Pharmacy and any of its Nevada- |
| registered/licensed staff members may be subject to discipline by the Board if the Pharmacy sells or |
| ships any compounded sterile product into Nevada without first obtaining written authorization from |
| the Board to do so. |
| 4. I certify that if the Pharmacy ever decides to sell or ship any compounded sterile |
| product into Nevada, the Pharmacy, through an authorized representative, will first notify the Board |
| and obtain written approval to sell and ship such products into Nevada. |
| 5. I understand that if the Pharmacy seeks approval to sell or ship compounded sterile |
| product into Nevada, an authorized representative of the Pharmacy may be required to appear |
| before the Board to answer questions before such approval is granted. |
| FURTHER AFFIANT SAYETH NOT. |
| I, Kyle Dresbach , do hereby swear under penalty of perjury that the assertions of this |
| affidavit are true. |
| IN THE A STANDING |
| SUBSCRIBED AND SWORN TO |
| before me, a notary public this 20 day of January 1, 20 20 \$ 20 20 20 20 20 20 20 20 20 20 20 20 20 |
| |



License Look Up

1/10/2020 2:18 PM

ScriptHero Pharmacy LLC

| Status | Active |
|-------------------------|--|
| Sub-Status | |
| Board | Board of Pharmacy |
| License Type | Terminal - Pharmacy - LIMITED Category 2 |
| License Number | 0234000008 |
| License Issue Date | 05/24/2019 |
| License Expiration Date | 03/31/2021 |
| License Effective Date | 05/24/2019 |
| Street Address | 2 Miranova PI 10th FI |
| City | Columbus |
| State | НО |
| Zipcode | 43215-5078 |
| Country | United States |
| Board Action | No |
| | |

Supervised By:

| End Date | |
|--------------------|------------------------------|
| Start Date | Mon May 13 00:00:00 GMT 2019 |
| Status | Active |
| Supervisor License | |
| Supervisor Name | KYLE DRESBACH |

Current date & time: 1/10/2020 2:18 PM

Delaware The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY "SCRIPTHERO PHARMACY LLC" IS DULY FORMED UNDER THE LAWS OF THE STATE OF DELAWARE AND IS IN GOOD STANDING AND HAS A LEGAL EXISTENCE SO FAR AS THE RECORDS OF THIS OFFICE SHOW, AS OF THE TWENTY-SEVENTH DAY OF JANUARY, A.D. 2020.

AND I DO HEREBY FURTHER CERTIFY THAT THE SAID "SCRIPTHERO PHARMACY LLC" WAS FORMED ON THE THIRD DAY OF DECEMBER, A.D. 2018.

AND I DO HEREBY FURTHER CERTIFY THAT THE ANNUAL TAXES HAVE BEEN PAID TO DATE.

7176487 8300 SR# 20200545792

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 202260065

Date: 01-27-20



VERIFICATION OF LICENSURE

BUSINESS NAME:

ScriptHero Pharmacy LLC

DBA

ScriptHero Pharmacy

LOCATION:

2 Miranova Pl 10th Fl

Columbus, OH 43215-5078

LICENSE NUMBER:

0234000008

TYPE OF LICENSE:

Terminal - Pharmacy - LIMITED Category 2

ORIGINAL LICENSURE DATE:

May 24, 2019

EXPIRATION DATE:

March 31, 2021

CURRENT LICENSE STATUS:

Active

CURRENT LICENSE SUB STATUS:

N/A

BOARD ACTION:

No

(If Board Action is "Yes", you may find more

information at elicense.ohio.gov)

DATE OF VERIFICATION:

1/30/2020

Karrie Southard Director of Licensing

State of Ohio Board of Pharmacy

State of Ohio Board of Pharmacy

77 South High Street, 17th Floor, Columbus, Ohio 43215 T: 614/466-4143 | F: 614/752-4836 | licensing@pharmacy.ohio.gov



LICENSE TO DISTRIBUTE DANGEROUS DRUGS

The entity named below is duly licensed, and is entitled to conduct business in the state of Ohio until March 31, 2021.

ScriptHero Pharmacy LLC

ScriptHero Pharmacy

2 Miranova Pl 10th Fl

Columbus, OH 43215-5078

License Number: 0234000008

Terminal - Pharmacy - LIMITED Category 2

Expiration Date: March 31, 2021

CLASS: Terminal - Pharmacy - LIMITED Category 2 BUSINESS TYPE: CR - Consulting Pharmacy Only

Responsible Person - Print, sign and keep license in a readily retrievable location at the address listed on this license.

Responsible Person Name (Print)

Signature of Responsible Person

KYLE DRESBACH RPH

Any change of responsible person must be reported within ten days of the effective date of the appointment of the new responsible person via Service Request on your Ohio eLicense Dashboard https://elicense.ohio.gov/oh_homepage.

State of Ohio Board of Pharmacy

77 South High Street, 17th Floor, Columbus, Ohio 43215
T: 614/466-4143 | F: 614/752-4836 | licensing@pharmacy.ohio.gov

Please note that the disciplinary actions described below do NOT pertain to operations at the location set forth in this application.

McKesson Corporation and its subsidiaries (hereinafter "McKesson") delivers pharmaceutical and medical products and business services to retail pharmacies and institutional providers like hospitals and health systems throughout North America and globally. Over the past 185 years, McKesson has developed multiple businesses that operate pharmacies, medical supply distribution centers, wholesale drug distribution centers, 3PL facilities, repackaging facilities, and other entities subject to federal and state regulation. Currently, McKesson owns and operates over 97 facilities in the United States that are licensed, permitted, or registered with the respective state agency with jurisdiction over its business type. Due to the breadth of its operations, it is practical that we limit this summary to disciplinary actions taken against these facilities during the last five years or the time frame specified in the question. The information in this statement is provided to the best of our knowledge and belief and includes all public disciplinary actions This statement does not include any fines that are deemed non-disciplinary by the issuing state (for example, it does not include non-disciplinary Citations and Fines issued by California). Please let us know if your state requires information regarding non-disciplinary fines

In 2015, McKesson entered into a Final Consent Order with the Maryland Board of Pharmacy concerning Landover DC. The Final Consent Order resolved allegations that, from January 2009 – December 2009, McKesson's Landover DC purchased approximately \$2.5 million of prescription drugs/devices from an unlicensed wholesale distributor. Since the period when the alleged violations occurred, McKesson has made numerous enhancements and significant additional investments in its compliance program related to the acquisition and distribution of pharmaceutical drug products. McKesson paid a \$15,000 fine in June 2015.

In 2016 McKesson Packaging Services, a business unit of McKesson Corporation was fined by the <u>California Board of Pharmacy</u> related to the fact that McKesson Packaging Services failed to timely notify the state of California when their designated representative left the company. The designated representative required by the home state was always in place. The new designated representative is now and has been since February 2, 2016 fully licensed. McKesson paid a \$500 fine. The fine is related to a non-disciplinary action.

In 2016 **McKesson Corporation** was fined by the <u>California Board of Pharmacy</u> related to the fact that its Washington Court House, OH distribution center failed to timely notify the state of California when their designated representative left the company. The designated representative required by the home state was always in place. The new designated representative is now and has been since August 6, 2014 fully licensed. McKesson paid \$400 fine. The fine is related to a non-disciplinary action.

In January 2017, **McKesson** entered into an agreement (the "DEA Settlement") with the <u>DEA and DOJ</u> to settle all potential administrative and civil claims stemming from investigation into McKesson's practices for identifying and reporting suspicious orders of controlled substances, beginning in 2009. Under the settlement McKesson agreed to pay \$150 million and to implement remedial measures related to its controlled substances monitoring program. In addition, the following distribution centers' DEA registrations were or will be suspended for the following specified products and time periods: Aurora, Colorado - all controlled substances from January 17, 2017 to January 17, 2020; Livonia, Michigan - all controlled substances from January 17, 2017 to

January 17, 2019; Washington Court House, Ohio - all controlled substances for the two-year period following completion of the Livonia suspension, from February 17, 2019 to February 17, 2021; and Lakeland, Florida - hydromorphone products from January 17, 2017 to January 17, 2018. The terms of the suspensions of the Livonia, Washington Court House, and Lakeland facilities permit those distribution centers to continue shipping controlled substances to customers that purchase products under McKesson's contract with the Department of Veterans Affairs.

In March 2017, in response to the DEA Settlement, the New York State Department of Health, Bureau of Narcotic Enforcement, suspended the Class 2A (Out-of-State) controlled substance license for McKesson's Livonia, Michigan distribution center. The permit was suspended until January 1, 2019, consistent with the suspension timeframes of the DEA Settlement. No other suspensions or fines were issued, and the New York action aligned with the suspension periods and expectations agreed to in the DEA Settlement.

In June 2017, in response to the DEA Settlement, the <u>Idaho Board of Pharmacy</u> suspended the Controlled Substance Registrations of **McKesson** distribution centers in Washington Court House, Ohio and the Livonia, Michigan. The Livonia Idaho controlled substance registration was suspended for two years, effective 6/17/17 to 1/17/19. The Washington Court House Idaho controlled substance registration is suspended for two years, effective 1/18/19 to 1/18/21. No other suspensions or fines were issued, and the Idaho action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In September 2017, in response to the DEA Settlement, the <u>Colorado State Board</u> of Pharmacy placed the wholesaler registration of **McKesson**'s distribution center-in Aurora, Colorado (14500 39th Ave) on probation. McKesson also agreed to pay a fine of \$45,000, with an additional surcharge of 15%, totaling \$51,750. No other suspensions or fines were issued.

In November 2017, in response to the DEA Settlement, the Louisiana Board of Pharmacy suspended the Controlled Substance Registrations of **McKesson** distribution centers in Washington Court House, Ohio and the Livonia, Michigan. The Livonia Louisiana controlled substance registration was suspended for two years, effective 6/17/17 to 1/17/19. The Washington Court House Louisiana controlled substance registration is suspended for two years, effective 1/18/19 to 1/18/21. McKesson also agreed to reimburse the Louisiana Board \$250.00 for administrative costs No other suspensions or fines were issued, and the Louisiana action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In December 2017, in response to the DEA Settlement, the New Hampshire Board of Pharmacy suspended the right of McKesson's distribution centers in Washington Court House. Ohio and Livonia, Michigan to distribute controlled substances. The Livonia distribution center's ability to distribute controlled substance was suspended, effective 12/12/17 to 1/17/19. The Washington Court House distribution center's ability to distribute controlled substance will be suspended for two years, effective 1/18/19 to 1/18/21. McKesson also agreed to pay an administrative fine of \$2,000.00. No other suspensions of fines were issued, and the New Hampshire action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

In February 2018, in response to the DEA Settlement, the <u>Florida Department of Business</u> & <u>Professional Regulation</u> and <u>McKesson Corporation</u> entered in a Settlement Agreement as

disposition of an alleged violation of Section 499.0121(10), Florida Statutes (2008-2017), by operating not in compliance with applicable federal laws and regulations. McKesson also agreed to pay a settlement amount of \$10,000.00. No other suspensions of fines were issued.

On March 14, 2018, in response to the DEA Settlement, the <u>lowa Board of Pharmacy</u> voted to issue Controlled Substance Act registrations for two of **McKesson Corporation**'s distribution centers. The Board issued the registrations pursuant to Controlled Substances Act Registration by Consent Agreements (the "Agreements"). The Agreements are applicable only to the registrations and do not impose discipline upon the distribution center's wholesale permits. The general terms of the Agreements are summarized below:

- Livonia, Michigan the facility's Iowa controlled substance registration was issued but was restricted. The facility was prohibited from distributing controlled substances into the state until 1/17/2019 except for various exceptions that mirror exceptions in the DEA settlement; and
- Washington Court House, Ohio the facility's lowa controlled substance registration was issued but is restricted and the facility will be prohibited from distributing controlled substances into the state from 1/18/19 to 1/18/2021 except for various exceptions that mirror exceptions in the DEA settlement.

On March 20, 2018, in response to the DEA Settlement, the Maryland State Board of Pharmacy suspended the right of McKesson's distribution center in Washington Court House, Ohio to distribute controlled substances. The distribution center's ability to distribute controlled substance will be suspended for two years, effective 1/18/19 to 1/18/21. No other suspensions of fines were issued, and the Maryland action aligns with the suspension periods and expectations agreed to in the DEA Settlement.

On April 9, 2018, in response to the DEA Settlement, **McKesson** entered into stipulations with the <u>Utah Board of Pharmacy</u>. The stipulations apply to the McKesson distribution centers located in Washington Court House, Ohio and Aurora, Colorado. The Washington Court House facility's right to distribute controlled substances into Utah has been suspended effective 1/18/2019 to 1/18/2021 and the Aurora facility's right to distribute controlled substances into Utah has been suspended from 4/9/2018 to 1/17/2020. The Utah Board of Pharmacy's action mirrors the suspension and exceptions agreed to in McKesson's settlement with the DEA Settlement.

In 2018 May McKesson Corporation was fined by the <u>California Board of Pharmacy</u> related to the fact that its Memphis, TN distribution center failed to timely notify the state of California when their designated representative left the company. The designated representative required by the home state was always in place. The new designated representative is now and has been since December 1, 2017 fully licensed. McKesson paid \$1,000 fine. The fine is related to a non-disciplinary action.

On May 31, 2018, in response to the DEA Settlement, McKesson entered into a consent agreement with the Oregon Board of Pharmacy (the "Oregon Consent"). The Oregon Consent applies to the McKesson distribution center located in Washington Court House, Ohio. The Washington Court House facility's right to distribute controlled substances into Oregon has been suspended effective 1/18/2019 to 1/18/2021. The suspension period imposed by Oregon aligns

with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On December 17, 2018, in response to the DEA Settlement, **McKesson** entered into a consent agreement with the <u>Virginia Board of Pharmacy</u> (the "Virginia Consent"). The Virginia Consent applies to the McKesson distribution center located in Livonia, Michigan. The Livonia facility's right to distribute controlled substances into Virginia was suspended until 1/17/2019. The suspension period imposed by Virginia aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On January 14, 2019 **McKesson Corporation** entered into a settlement for a payment of \$10,000 on behalf of a now-closed facility in <u>Connecticut</u>. This settlement arose from the failure of employees of McKesson's contracted local delivery carrier to secure their vehicles when making deliveries within Connecticut. Importantly, there were never any reports of theft or loss based on this failure and McKesson's contract with the local delivery carrier specifically required security measures, including the securing of vehicles.

On February 27, 2019, in response to the DEA Settlement, McKesson entered into a consent agreement with the Wisconsin Pharmacy Examining Board (the "Wisconsin Consent"). Under the terms of the consent, the Livonia, Michigan facility was fined and the facility's right to distribute controlled substances into Wisconsin was suspended from 1/17/17 to 1/17/19. The Washington Court House, Ohio facility was fined and the facility's ability to distribute controlled substances into Wisconsin has been suspended effective 1/17/19 to 1/17/2021. The suspension period imposed by Wisconsin aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On May 10, 2019, in response to the DEA Settlement, McKesson entered into the stipulated agreement with the New Mexico Board of Pharmacy (the "New Mexico Agreement"). The New Mexico Agreement applies to the McKesson distribution center located in Washington Court House, Ohio. The facility's ability to distribute controlled substances into New Mexico has been suspended until February 16, 2021. The suspension period imposed by Wisconsin aligns with the federal DEA suspensions and with those imposed by other states that have taken reciprocal action based on the DEA Settlement.

On May 21, 2019, in response to the DEA Settlement, **McKesson** entered into a consent order with the <u>Alabama Board of Pharmacy</u> (the "Alabama Consent"). The Alabama Consent applies to the McKesson distribution centers located in Washington Court House, Ohio, Aurora, Colorado and Livonia, Michigan. Under the terms of the Alabama Consent, each facility was subject to a fine of fifteen thousand dollars (\$15,000).

On June 10, 2019, in response to the DEA Settlement, McKesson entered into a consent agreement with the <u>Virginia Board of Pharmacy</u> (the "WCH Virginia Consent"). The WCH Virginia Consent applies to the McKesson distribution center located in Washington Court House, Ohio. The facility's right to distribute controlled substances into Virginia has been suspended from June 10, 2019 to February 16, 2021. The WCH Virginia Consent originates from McKesson's report to Virginia of settlements that McKesson entered into with the DEA and Louisiana Board of Pharmacy.

On July 29, 2019, in response to the DEA Settlement, the <u>California Board of Pharmacy</u> approved a Stipulated Settlement and Disciplinary Order for Public Reproval with **McKesson** (the "California Settlement"). The California Settlement is effective on August 28, 2019 and applies to the Washington Court House, Ohio distribution center. Subject to the terms of the settlement, McKesson was issued a public letter of Reproval, agreed to pay \$4,000 in investigative fees.

On August 29, 2019 McKesson received a Letter of Admonition from the <u>Colorado State</u> <u>Board of Pharmacy</u> due to the delinquent notification of a change in the Designated Representative at its distribution center located at in O'Fallon, MO ("McKesson St. Louis").

On August 29, 2019 McKesson entered into a Stipulation and Final Agency Order with the <u>Colorado State Board of Pharmacy</u> regarding the delinquent notification of a change in the Designated Representative at its distribution center located in Aurora, IL ("McKesson Chicagoland"). The terms of the settlement included a fine in the amount of \$1,150.00.

On January 7, 2020 McKesson entered into a Consent Agreement and Final Order with the <u>Iowa Board of Pharmacy</u> regarding pseudoephedrine products had not been included in the McKesson's Clear Lake, IA facility's annual controlled substance inventory and that butalbital products continued to be treated as legend drugs after such products became schedule III products in the state on June 26, 2019.

Pending Actions

The <u>Indiana Board of Pharmacy</u> issued a complaint and **McKesson Corporation** responded but have not had further communication with the Board.

The Georgia Board of Pharmacy issued a proposed consent order and McKesson Corporation is responding but have not finalized any agreement with the state.

The <u>Delaware Board of Pharmacy</u> issued a proposed consent order and **McKesson** Corporation is responding but have not finalized any agreement with the state.

The <u>Illinois Department of Financial and Professional Regulation</u> informed **McKesson** Corporation that the state would be seeking disciplinary action against Illinois licensed facilities. Please note that for the above-referenced pending actions, no final action has been taken and all

Thomas Gilbert Traylor, III

Date -

Nevada State Board Of Pharmacy

(Firm mailing address for window envelope)
THIS STUB IS YOUR RECEIPT

Date: 02/13/2020 Amount: \$ 500.00 License #: PH04194

ScriptHero Pharmacy LLC 2 Miranova PI, 10th FI Columbus OH 43215

(ID Card)

Pharmacy

Expires:09/20/2020

ScriptHero Pharmacy LLC 2 Miranova PI, 10th FI Columbus OH 43215

License # PH04194 Temporary

NEVADA STATE BOARD OF

PHARMACY

IDENTIFICATION ONLY
DOES NOT MEET POSTING REQUIREMENTS

Trim ID Card to fit your wallet

NEVADA STATE BOARD OF PHARMACY

Pharmacy

Expires: 09/20/2020 STATUS: Temporary

License Type: Pharmacy License #: PH04194

THE UNDER-NOTED HAVING PAID STATUTORY FEE IS HEREBY LICENSED

Managing Pharmacist:

ScriptHero Pharmacy LLC 2 Miranova Pi, 10th FI Columbus OH 43215

NONTRANSFERABLE

POST THIS LICENSE PROMINENTLY IN A CONSPICUOUS PLACE

Reprinted: 03/20/2020.



Renaissance One Two North Central Avenue Phoenix, AZ 85004-2391 602-229-5200 Fax 602-229-5690 www.guarles.com

Attorneys at Law in Chicago Indianapolis Madison Milwaukee Minneapolis Naples Phoenix Tampa Tucson Washington, D.C.

Writer's Direct Dial: 602-229-5439 E-Mail: Nicholas.Meza@quarles.com

March 19, 2020

VIA E-MAIL

J. David Wuest
Executive Secretary
dwuest@pharmacy.nv.gov
Nevada State Board of Pharmacy
985 Damonte Ranch Pkwy, Ste 206
Reno, NV 89521

Re: Request for Temporary Permit

Executive Secretary Wuest:

I hope this letter finds you well. Quarles & Brady LLP represents ScriptHero Pharmacy LLC ("ScriptHero Pharmacy"). We write to respectfully request that you issue a temporary nonresident pharmacy permit to ScriptHero Pharmacy pursuant to your authority and discretion under Nev. Admin. Code § 639.200.

ScriptHero Pharmacy is a non-dispensing, closed-door pharmacy located in Columbus, Ohio. The pharmacy is affiliated with McKesson Corporation. ScriptHero Pharmacy does not adjudicate claims, handle controlled substance prescriptions, or dispense medications of any kind.

As you know, ScriptHero Pharmacy was summoned to appear before the Nevada State Board of Pharmacy's (the "Board") Thursday, March 19, 2020 meeting for consideration of ScriptHero Pharmacy's nonresident pharmacy application. The meeting was canceled due to the COVID-19 outbreak. It is our understanding that ScriptHero Pharmacy was called before the Board due to an affirmative response on Question 3 of the disciplinary history section of the nonresident pharmacy application. The question at issue broadly asks if the *corporation*, its *owners*, *shareholders* or *partners* with interest, have ever been subject to administrative action relating to the pharmaceutical industry. Because ScriptHero Pharmacy is owned by McKesson, ScriptHero Pharmacy answered in the affirmative to Question 3 and appropriately disclosed McKesson's disciplinary history. Of note, the applicant, ScriptHero Pharmacy, has never been the subject of any investigation or disciplinary action by any regulatory body.

J. David Wuest, Executive Secretary Nevada State Board of Pharmacy March 19, 2020 Page 2

Due to the uncertainty brought on by the COVID-19 outbreak, including the Board postponing its March 19th and potentially future meetings, and travel restrictions put in place by employers across the country, issuance of a temporary permit in this instance is warranted. The issuance of a temporary permit to ScriptHero Pharmacy will allow, among other things, the pharmacy to perform non-dispensing pharmacy services in the state. As such, we respectfully request that ScriptHero Pharmacy be issued a six-month temporary permit. ScriptHero Pharmacy is optimistic that, after six months, public meeting and travel restrictions will ease and ScriptHero Pharmacy representatives will be available to physically appear before the Board and answer whatever questions the Board may have regarding the pharmacy's operations.

Thank you for your consideration. Should you need additional information, please do not hesitate to contact me.

Very truly yours,

Nicholas H. Meza

NHM:cf

CC: Brett Kandt General Counsel Nevada State Board of Pharmacy 775-850-1440 bkandt@pharmacy.nv.gov